Introduction
Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) characterized by overproduction of red blood cell and erythrocytosis, which is often associated with thrombocytosis and leukocytosis. 1 Thrombotic complications and transformation into myelofibrosis (post-PV MF) or acute myeloid leukemia (AML) represent distinctive events during the course of the disease. Advanced age and previous thrombosis are established risk factors for thromboembolic complications. 2 Leukocyte count exceeding 15 Â 10 9 /l and long disease duration have been reported to predict the risk of post-PV MF. 3, 4 White blood cell (WBC) count 415 Â 10 9 /l and advanced age are recognized as poor prognostic factors for progression to AML. 5, 6 An identical gain-of-function mutation of JAK2 is found in approximately 95% of patients with PV. 7 According to a two-step model, 8 the occurrence of JAK2 (V617F) gives rise to a heterozygous clone that expands to replace hematopoietic cells without the JAK2 mutation. The second step would consist of a mitotic recombination in a hematopoietic cell heterozygous for JAK2 (V617F) that later generates uniparental disomy. The daughter cell that is homozygous for JAK2 (V617F) gives rise to a new clone that expands and replaces the heterozygous clone. As clonal cells carrying the mutation may coexist with hematopoietic cells that do not carry JAK2 (V617F), variable proportions of JAK2 (V617F) mutant alleles are found in myeloid cell populations. 7, 9 In terms of JAK2 (V617F) mutant alleles, the first step is characterized by a progressive increase from 0 to 50%, whereas the second step from 50 to 100%.
A mutant allele dosage effect on clinical phenotype has been described in PV and patients with high mutant allele burden have been found to have a more severe disease. [10] [11] [12] Retrospective studies have shown that patients bearing homozygous JAK2 (V617F) are more likely to progress to post-PV MF. 10, 12, 13 Moreover, patients with post-PV MF have the highest values for mutant allele burden within MPNs. 3, 7 To better define the effect of the JAK2 (V617F) mutant allele burden on clinical phenotype and disease progression, we prospectively studied a cohort of PV patients.
Patients and methods

Study population and definitions
This prospective observational cohort study included 338 patients with PV diagnosed and followed at the Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Italy, between 2002 and August 2009. This study was approved by the institutional ethics committee (Comitato di Bioetica, Fondazione IRCCS Policlinico San Matteo). The procedures followed were in accordance with the Helsinki Declaration of 1975, as revised in 2000, and samples were obtained after patients provided written informed consent.
The prospective observation started from the evaluation of the JAK2 (V617F) allele burden: 155 patients (46%) entered the study at diagnosis and 183 (54%) during the course of PV in stable phase (median time from diagnosis 4.7 years, range, 1-25). All patients were regularly followed after the JAK2 (V617F) evaluation with at least three visits per year. Patients were treated according to their risk of thromboembolic complications irrespective of JAK2 mutant allele burden. 2 High-risk patients (age equal to or 460 years, or previous thrombosis) received cytoreductive therapy. Low-risk patients (age under 60 years, no previous thrombosis) received phlebotomy, while cytoreductive therapy was added in the case of progressive leukocytosis or thrombocytosis, presence of constitutional symptoms or increasing spleen size. Low-dose aspirin was given if not contraindicated. 14 Diagnosis of PV was in accordance with the WHO (World Health Organization) criteria. 15 The International Working Group on MPNs Research and Treatment criteria were applied to define transformation into post-PV MF, 16 and the WHO criteria were adopted for diagnosis of AML. 15 The decision to check bone marrow to evaluate potential disease evolution was on a clinical basis. For the assessment of bone marrow fibrosis, paraffin sections were stained with Gomori's silver impregnation technique, and fibrosis was assessed semi-quantitatively following the European consensus guidelines. 17 Major thrombotic events included ischemic stroke, cerebral transient ischemic attack, acute myocardial infarction, peripheral arterial thrombosis, venous thromboembolism including deep vein thrombosis of the extremities or of abdominal vein and pulmonary embolism. Major bleeding consisted of any hemorrhage leading to hospital admission.
Study objectives
The objectives of the study were to investigate the relationship between the mutant allele burden and clinical phenotype at diagnosis, and to define the role of mutant allele burden in the prediction of disease-related complications. In patients at diagnosis, we analyzed the association between the JAK2 (V617F) allele burden and the presenting features (age, sex, hemoglobin value, WBC count, platelet count, serum lactate dehydrogenase activity, circulating CD34-positive cells, bone marrow age-adjusted cellularity and fiber content, pruritus, spleen and liver size). In the whole series, we studied the relationship between the JAK2 (V617F) allele burden and the rate of major thrombosis (arterial and venous), the occurrence of major hemorrhages and transformation into MF or acute leukemia.
JAK2 mutational analysis
Granulocyte JAK2 (V617F) mutation burden was assessed using a quantitative PCR-based allelic discrimination assay. 18 PCR was performed on a RotorGene 6000TM real-time analyzer on a 100-well Gene Disk (Corbett Life Sciences, Mortlake, NSW, Australia) in two separate tubes for normal and mutated alleles. In all, 40 nanograms of genomic DNA were amplified in a 40-cycle PCR at an annealing temperature of 55 1C. All reactions were carried out in a final volume of 12 ml containing 1 Â Brilliant SYBR Green QPCR master mix (Stratagene, Cedar Creek, TX, USA) and 300 nM of both forward and reverse primers. Serial dilutions, starting at 80 ng/ml and ending at the 0.4 ng/ml, of both a wild type and a fully mutated DNA were used to construct standard curves from which the wild type and V617F quantities were calculated for each sample. Results were expressed as percentage of V617F alleles among total JAK2 alleles (WT þ V617F). The method was periodically checked assaying the specimens for JAK2 (V617F) status distributed internationally by United Kingdom National External Quality Assessment Service. Direct genomic sequencing was used for the identification of JAK2 exon 12 mutations. 19 
Statistical analysis
Comparisons of categorical variables between groups were carried out using the w 2 test for tables, while numerical variables were compared using nonparametric tests such as Mann-Whitney and Kruskal-Wallis. The nonparametric Spearman rank correlation was used to test for correlation between JAK2 (V617F) mutation burden and ordinal clinical variables. Time-to-event analyses (either vascular events or disease transformation) were carried out accounting for lefttruncation of the individual records, that is, considering each patient at risk from diagnosis, but defining the date of JAK2 assessment as the time of entry in the study. Survival analyses were carried out using Cox proportional hazards regression models, while survival curves were obtained from Kaplan-Meier estimates. Analyses were carried out using Stata SE 9 (StataCorp LP, College Station, TX, USA), Statistica 8 (StatSoft Inc., Tulsa, OK, USA) and Microsoft Excel 2000 (Redmond, WA, USA). Figure 1 shows the JAK2 mutational status of 338 patients enrolled in the study. Table 1 summarizes baseline demographics and clinical characteristics of the 320 JAK2 (V617F)-positive patients. With respect to the risk of thrombosis, a high-risk profile was present in 79 (54%) patients who entered the study at diagnosis and in 115 (66%) of those entered during the course of the disease. Regarding leukocyte count, 121 (37%) patients had leukocytosis (WBC over 11 Â 10 9 /l), while 40 (12%) had an extreme leukocytosis (WBC over 15 Â 10 9 /l). Median follow-up after JAK2 mutation evaluation was 3.2 years (range 0.6-7.5 years), without significant differences between patients entered at diagnosis or during follow-up. At the end of observation, 269 (84%) patients had received cytoreductive therapy, and 51 (16%) phlebotomy alone. Aspirin was given to Figure 1 Description of the study: 338 patients with PV were enrolled into the study. The upper box shows allocation of JAK2 mutations among patients according to three categories: JAK2 (V617F) mutation, JAK2 exon 12 mutations and JAK2-negative.The lower boxes show how disease complications are distributed between the two categories of JAK2 mutant allele burden: low-mutant burden (o50% mutant alleles), and high-mutant burden (X50% mutant alleles).
Results
Molecular status and patients' characteristics
JAK2 (V617 F) allele burden in polycythemia vera F Passamonti et al 280 (87%) patients. Median JAK2 mutant allele burden of the whole cohort of PV patients was 47% (range 1-100%). Spearman rank correlation showed a direct association between disease duration and JAK2 (V617F) allele burden (r ¼ 0.21; Po0.001). This is reflected in a different distribution of disease duration between patients with o50% mutant alleles and those with 450% (Mann-Whitney U-test: P ¼ 0.001).
Among the remaining PV patients, 14 (4.1%) had exon 12 mutations of JAK2 and 4 (1.2%) did not carry any JAK2 mutation in spite of the clinical features of PV (Table 2) .
Genotype-phenotype relationship at diagnosis
In patients with PV at diagnosis, the Spearman rank correlation test showed a significant direct relationship between JAK2 mutant allele burden and hemoglobin concentration (r ¼ 0.27, P ¼ 0.001), WBC count (r ¼ 0.26, P ¼ 0.001), spleen size (r ¼ 0.25, P ¼ 0.001), bone marrow cellularity (r ¼ 0.27, P ¼ 0.009) and age-adjusted bone marrow cellularity (r ¼ 0.33, P ¼ 0.002). By contrast, there was an inverse relationship between the proportion of JAK2 mutant allele burden and platelet count (r ¼ -0.27, Po0.001). Patients with pruritus had significantly higher JAK2 (V617F) allele burden than those without (P ¼ 0.0003).
When categorizing patients according to the proportion of JAK2 mutant alleles, Mann-Whitney U-test showed that patients with an allele burden equal to or 450% had significantly higher WBC count (P ¼ 0.001), greater spleen size (P ¼ 0.01) and lower platelet count (Po0.001) than those with an allele burden o50%. We did not find significant differences in term of thrombotic complications among the two groups. In detail, thrombosis pre-or at diagnosis occurred in 17 (19%) patients with an allele burden below 50% and in 16 (28.6%) patients with an allele burden above 50%.
JAK2 (V6127F) allele burden and risk of vascular complications
During follow-up, 20 (6.2%) patients developed major thrombotic events: 9 in patients enrolled at diagnosis and 11 in those entered during course. In total, 14 of these 20 patients (70%) had arterial thrombosis, including acute myocardial infarction (n ¼ 3), ischemic stroke and transient ischemic attack (n ¼ 10), and peripheral arterial thrombosis (n ¼ 1). Six (30%) patients had venous thrombosis as deep venous thrombosis of the extremities (n ¼ 3) and of abdominal veins (n ¼ 3). Figure 1 shows the distribution of vascular events in patients with an allele burden below or above 50%. Survival analysis was carried out accounting for left censoring of the observation. Cox proportional hazard regression showed that the JAK2 mutant allele burden, analyzed either as a continuous or categorical variable, did not significantly correlate with the risk of thrombosis. Multivariable analysis including different covariates (Table 3) showed that only advanced age has a significant effect on thrombosis (P ¼ 0.01). In this model, leukocytosis defined as WBC count exceeding 11 Â 10 9 /l did not affect the occurrence of subsequent thrombosis. The same result was obtained in a further model including WBC over 15 Â 10 9 /l as covariate. Five patients had severe episodes of bleeding (gastric in four and cerebral in one). No relationship was found between JAK2 mutant allele burden and the risk of hemorrhage.
JAK2 (V617F) allele burden and disease transformation
During the study period, disease transformation occurred in 18 (5.6%) patients (Figure 1) . Eight patients, all with 450% JAK2 (V617F) mutant alleles at study entry, progressed to post-PV MF, JAK2 (V617 F) allele burden in polycythemia vera F Passamonti et al while 10 developed AML (8 with 450% JAK2 mutant alleles at baseline, of whom 3 went through a post-PV MF phase). All four patients studied for JAK2 at the time of AML evolution were JAK2 (V617F)-positive (three passing through post-PV MF). As JAK2 mutant allele burden was measured at different times since diagnosis, and assuming a potential effect of time on allele burden and on disease transformation, a survival analysis with left truncated data was performed. With respect to the risk of progression to post-PV MF, the JAK2 mutant allele burden, considered as a continuous variable, significantly correlated with the risk of MF (hazard ratio: 1.04, 95% confidence interval: 1.004-1.08; P ¼ 0.029). This implies that a 10% difference in allele burden between two subjects corresponds to a 40% increase in risk of post-PV MF. A multivariable analysis including different covariates (Table 3) showed that only mutant allele burden significantly affects the occurrence of MF (P ¼ 0.03). In this model, leukocytosis (WBC over 11 Â 10 9 /l) did not affect post-PV MF as well as a higher cutoff of leukocyte count (15 Â 10 9 /l) obtained in a further model. Figure 2 plots Kaplan-Meier estimates of MF-free survival according to JAK2 allele burden categories. We evaluated clinical picture of the eight post-PV MF patients at the time of enrollment: hemoglobin values ranged from 14.1 g per 100 ml to 16.5 g per 100 ml, no patients showed leukoerythroblastosis or splenomegaly and all were on cytotoxic therapy. Median follow-up of these patients was not significantly different from that of patients who did not progress to post-PV MF (2.7 vs 4.3 years, P ¼ 0.32).
Analyzing the risk of AML, Cox proportional hazard regression showed that the JAK2 mutant allele burden, evaluated either as a continuous or categorical variable, did not significantly affect progression to AML. Multivariable analysis including different covariates (Table 3) showed that advanced age effects on AML occurrence with a borderline significance (P ¼ 0.06). When testing in the model WBC count over 15 Â 10 9 /l as covariate, leukocytosis (P ¼ 0.06) and advanced age (P ¼ 0.05) had a borderline effect on AML.
JAK2 (V6127F) allele burden and survival
Among 320 patients, 17 (5.3%) died. Causes of death were AML in 10 patients, ischemic stroke in 3, myocardial infarction in 1, portal hypertension in 1, uterine cancer in 1 and unknown cause in 1. Cox proportional hazard regression showed that the JAK2 mutant allele burden, analyzed as a continuous or categorical variable, did not affect survival. Multivariable analysis including different covariates (Table 3) showed that only advanced age affects survival (P ¼ 0.002). In this model leukocytosis (WBC over 11 Â 10 9 /l) did not affect survival as well as a higher cutoff of leukocyte count (15 Â 10 9 /l) obtained in a further model.
Discussion
The findings of this study indicate that the JAK2 (V617F) allele burden varies considerably in PV, and that this variability at least in part contributes to determining both phenotypic manifestations and clinical course of this MPN. These results are obtained in a cohort of 320 PV patients followed for a median prospective observation of 3.2 years.
The vast majority of PV patients studied carried a mutation of the JAK2 gene, namely JAK2 (V617F) in 94.7% or JAK2 exon 12 mutations in 4.1%. This is in keeping with previous observations based on the use of sensitive detection methods. 10, [20] [21] [22] [23] However, there was a small subgroup of patients who satisfied the WHO criteria for diagnosis of PV, but were consistently negative for JAK2 mutations on granulocytes. Our quantitative reverse transcriptase-PCR-based allelic discrimination assay for JAK2 (V617F) has now a detection limit of 0.2% mutant alleles, while direct sequencing applied for JAK2 exon 12 mutations of 10% mutant alleles. A low level of mutation-bearing cells may explain the JAK2-negative status of these patients; alternatively, other as-yet-unknown mutations may be responsible for the PV phenotype.
The relationship found in this study between JAK2 mutant allele burden and presenting features provides further evidence that JAK2 (V617F) is a determinant of clinical phenotype in PV. 10, 11, [24] [25] [26] [27] In fact, a significant direct correlation was found between the proportion of mutant alleles and hemoglobin level and WBC count, while there was an inverse relationship with platelet count. A pathophysiological basis for these relationships has been provided by experimental studies. Tiedt et al.
28 Table 3 Multivariable analysis including clinical parameters at JAK2 assessment in 320 patients with polycythemia vera JAK2 (V617 F) allele burden in polycythemia vera F Passamonti et al generated JAK2 (V617F) transgenic mice using a human JAK2 gene, and found that the ratio of mutant to wild-type JAK2 was critical for the myeloproliferative phenotype of these animals. Mice with low mutation burden had a phenotype resembling essential thrombocythemia, those with intermediate burdens had also erythrocytosis and leukocytosis, and those with high burdens had a PV-like phenotype without thrombocytosis. Studies of JAK2 (V617F) expression in murine cells 29 suggest that low levels of JAK2 kinase activity favor thrombocytosis whereas high levels favor erythrocytosis. Indeed, with respect to platelet production an inverse relationship has been observed between JAK2 (V617F) alleles and expression of thrombopoietin receptors. 30 In this prospective analysis, we did not find differences in term of risk of thrombosis during follow-up between patients with an allele burden o50% and those with an allele burden equal to or 450% at baseline. Many factors participate to the thrombophilic diathesis of PV.
2 Among these, age, cardiovascular risk factors and genetic thrombophilia are independent from the JAK2 mutational status. Cytoreductive therapy as well as aspirin are effective treatments for thrombosis prevention, 14, 31 therefore masking the potential thrombophilic role of the mutation. Two large studies on PV did not reveal a relationship between JAK2 mutant allele burden and thrombosis, 10, 25 while one found a correlation. 11 These studies, however, are heterogeneous regarding the population sample, DNA source and percentages of patients receiving cytotoxic agents. Among the different covariates studied in a multivariate analysis, we found that advanced age is the only significant predictor of thrombosis, as expected. Previous thrombosis, identified by many groups as predictors of vascular complications, 4, 5, 32 did not affect on thrombosis in our study. This probably depends by our treatment strategy, based on risk stratification at enrollment, which reduced differences of events during follow-up among lowand high-risk patients. Our study did not show a prognostic role for WBC count tested at different cutoff (over 11 Â 10 9 /l and over 15 Â 10 9 /l) to predict thrombosis during follow-up. In contrast, we found a significant difference in term of MF-free survival by comparing patients with JAK2 (V617F) allele burden o50% with those with a mutant allele burden equal to or 450%. The direct relationship between mutant load and the risk of MF retained prognostic significance after adjusting for potential confounders in multivariate analysis. Leukocytosis failed to show a role on the prediction of post-PV MF. For the analysis of event-free survival, we considered left censoring of the observations to account for the potential effect of time on JAK2 allele burden and on progression to post-PV MF. Regarding the effect of time on allele burden, it has been reported that over a few years from the first evaluation, allele burden seems stable in MPNs when studied in sequential evaluations of individual patients, with the exceptions of few cases. 33, 34 In a previous study, we have reported that allele burden of post-PV MF is significantly higher than that of PV and this corresponds to different clinical phenotypes. 7 In this paper, we showed that allele burden confers different clinical phenotypes and risks of disease evolution. It is possible that unknown inter-individual determinants, other than time per se, may most likely determine allele burden variation. Regarding the effect of time on progression to post-PV MF, a study on 647 PV patients showed that a long PV duration does not predict higher risk of post-PV MF. 3 The relationship we found in a prospective analysis between JAK2 allele burden and subsequent post-PV MF confirms the observations of previous retrospective studies. 10, 12, 13 We state that mutant allele burden is a risk factor for disease progression into post-PV MF. We can not drive any conclusion on the pathogenetic role of allele burden on MF occurrence. On this topic, mouse models 35 with retroviral transduction of bone marrow with JAK2 (V617F) results in clinical-pathological features of PV with increasing spleen size and bone marrow fibrosis over time. Moreover, in an inducible knock-in mouse model, homozygous JAK2 (V617F) resulted in a PV-like disease associated with a significantly larger spleen size, and accelerated bone marrow fibrosis when compared with heterozygous JAK2 (V617F). 36 The risk of developing AML was not significantly related to the mutant allele burden. In fact, irrespective of the JAK2 (V617F) mutational status, additional oncogenic events likely participate in leukemic transformation. 37 This is shown by the high rate of patients showing a complex karyotype, 38, 39 and by the several additionally altered regions identified with SNP-chip analysis 40 at leukemic transformation. Our results parallel those obtained in primary MF, 41, 42 in which a relationship between JAK2 mutant allele burden and leukemia was not evident. Regarding other risk factors, we found that advanced age may predict AML occurrence although with a borderline significance. It 0 s interesting to note that patients with extreme leukocytosis (WBC count over 15 Â 10 9 /l) have a high risk of developing AML, as already reported by other investigators. 5 In conclusion, this study indicates that in PV patients a high JAK2 mutant allele burden is a risk factor for transformation into MF. Understanding the pathogenesis of PV and its complications represents the basis for molecularly tailored treatments of the disease. New agents with anti-JAK2 properties are being analyzed in clinical trials. 43 Studies in PV patients will clarify whether a reduction of the allele burden by treatment may prevent evolution into MF.
